Achieving turnkey purification workflows on complicated drug modalities
Streamlining workflows for higher productivity, sample purity and recovery are primary goals for any laboratory working within the field of preparative liquid chromatography. However, the path to success can vary widely. In this exclusive webinar series, produced in partnership with Agilent Technologies, experts from three different application areas will share their experiences and best practices to help you overcome the key challenges and setbacks associated with preparative HPLC.
Webinar 1 of Best practices to overcome challenges in preparative HPLC webinar series (November 03, November 10, & November 24)
Achieving turnkey purification workflows on complicated drug modalities
As of today, there are 10 approved antibody-drug conjugates (ADCs) against a spectrum of oncology targets. The promise of antigen-targeted drug delivery via targeted antibodies has now become a reality. With the increased demands of novel ADCs, a bottleneck commonly resides with the dual modality purification of the small molecule ‘linker payload’, the naked antibody and combined antibody drug conjugate macromolecules. In this webinar, Ed Ha, Principal Scientist at Angiex, will showcase a collection of optimized workflows for small and large molecule quantification, and post-prep workflows, while providing top tips for identifying repetitive and unproductive steps.
Presenter: Ed Ha (Founding Principal Scientist, Angiex in Cambridge, MA)
Ed Ha is Founding Principal Scientist at Angiex in Cambridge, MA, USA, where he is responsible for establishing chemistry, analytics and bioconjugation strategies. Over 21 years, Ed has investigated the synthesis of natural product-inspired payloads towards conjugation to antibodies. He joined Genentech in 1999 within its 1st Parallel Synthesis group. Within a few months, he joined the inaugural Antibody Drug Conjugate (ADC) group synthesizing novel cytotoxic payloads such as the microtubule inhibitors, maytansinoids and auristatins.
In 2005, Ed followed the ADC project and joined the 1st Small Molecule Process group to deliver payloads, linkers and kinase inhibitors for IND-enabling studies. T-DM-1 was approved in 2013 for Her-2-positive metastatic breast cancer with the trade name Kadcyla.
After 10-years at Genentech, Ed helped build chemically driven conjugation methods at Igenica and studied oligonucleotide conjugates and enzymatic conjugations at Solstice Biologics. Ed’s 1st undergraduate project was solution-phase oligonucleotide at Washington University in St. Louis, USA. After a summer internship at Monsanto within the transition metal-mediated chemistry group, Ed commenced graduate studies in molecular recognition at UCLA.
Presenter: Carrie Haslam (Associate Editor, SelectScience)
Carrie Haslam is an Associate Editor at SelectScience, playing a key role in content production and specializing in Alzheimer’s disease and clinical diagnostics. She is finalizing her Ph.D. from Plymouth University, UK, where she developed graphene-based biosensors for the early diagnosis of Alzheimer’s disease.
